www.idosr.org
Nagawa, 2025
©IDOSR PUBLICATIONS
ISSN: 2579-0730
International Digital Organization for Scientific Research
IDOSR JBCP/25/101.303500
IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY 10(1):30-35, 2025.
https://doi.org/10.59298/IDOSR/JBCP/25/101.303500

Cellular and Humoral Immunity in Congenital Blood and Bleeding Disorders

Nagawa Jackline Irene

Department of Clinical Medicine and Dentistry Kampala International University Uganda
Email: irene.nagawa@studwc.kiu.ac.ug

ABSTRACT

Congenital blood and bleeding disorders encompass a range of inherited conditions that affect hematopoiesis, coagulation, and immune function. These disorders often impair both cellular and humoral immunity, leading to increased susceptibility to infections, immune dysregulation, and autoimmunity. Cellular immunity, mediated by T cells, macrophages, and NK cells, is significantly affected in conditions such as severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and sickle cell disease (SCD). Humoral immunity, dependent on B cells and antibody production, is compromised in disorders like common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA), resulting in poor immune responses. Additionally, congenital bleeding disorders such as hemophilia and von Willebrand disease (VWD) can trigger immune complications, including inhibitor development and alloimmunization. Therapeutic strategies such as gene therapy, bone marrow transplantation, immunoglobulin replacement, and vaccination aim to mitigate these immune challenges. Understanding the complex interplay between immune dysfunction and congenital blood disorders is essential for optimizing patient management and developing targeted interventions to improve outcomes.

Keywords: Congenital blood disorders, Cellular immunity, Humoral immunity, Immunodeficiency, Gene therapy

INTRODUCTION

Congenital blood and bleeding disorders represent a broad spectrum of inherited conditions that affect hematopoiesis, coagulation, and immune function [1] These disorders disrupt the delicate balance of immune homeostasis, leading to increased susceptibility to infections, immune dysregulation, and chronic inflammation [2]. While hematological abnormalities are the defining features, the impact on both cellular and humoral immunity is profound, making affected individuals vulnerable to opportunistic infections and autoimmune complications. Understanding the intricate interactions between the immune system and these disorders is essential for developing targeted therapeutic strategies that enhance immune function while managing hematologic abnormalities [3] Hematopoiesis, the process by which blood cells are produced in the bone marrow, plays a pivotal role in immunity. Any disruption in this process can lead to deficits in immune cell populations, altering both innate and adaptive immune responses [4] Many congenital blood disorders, such as severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), Diamond-Blackfan anemia (DBA), sickle cell disease (SCD), and thalassemia, significantly impair immune cell production and function [5] In some cases, immune dysregulation results in autoimmunity, further complicating disease management.

The immune system consists of two primary components: cellular and humoral immunity. Cellular immunity, mediated by T lymphocytes, macrophages, and natural killer (NK) cells, is responsible for pathogen recognition and elimination [6]. Humoral immunity, mediated by B lymphocytes and immunoglobulins, ensures long-term protection through antibody production. In congenital blood disorders, both arms of immunity are frequently compromised, leading to an inadequate defense against infections and poor vaccine responses [7]. Furthermore, chronic inflammation and oxidative stress associated with hemoglobinopathies like sickle cell disease and thalassemia contribute to immune exhaustion, further diminishing immune efficacy [8]

Another critical aspect of congenital blood disorders is their impact on the thymus and bone marrow, which are essential for immune cell development. For instance, in SCID, genetic mutations lead to profound defects in T-cell development, leaving affected individuals highly susceptible to life-threatening infections [9]. Similarly, in DBA, ineffective erythropoiesis is often accompanied by reduced lymphocyte numbers, impairing immune responses. In hemoglobinopathies, chronic hemolysis and iron overload contribute to immune dysfunction, further exacerbating infection susceptibility [10].

Cellular Immunity in Congenital Blood Disorders

Cellular immunity is fundamental to host defense, as it enables the body to recognize and eliminate pathogens [11]. However, in congenital blood disorders, cellular immune responses are often defective due to bone marrow abnormalities, chronic inflammation, and genetic mutations affecting immune cell function. Several congenital blood disorders are characterized by significant T-cell dysfunction, which predisposes individuals to recurrent infections, inflammatory complications, and an increased risk of malignancy [12] SCID is one of the most severe congenital immunodeficiency disorders, characterized by a complete or near-complete lack of functional T cells [13]. Without intervention, affected infants suffer from recurrent, life-threatening infections and fail to thrive. In SCID, genetic mutations disrupt T-cell receptor signaling, cytokine signaling, or V(D)J recombination, leading to profound immune impairment. Hematopoietic stem cell transplantation (HSCT) remains the standard curative therapy, but gene therapy is emerging as a promising alternative [14] Wiskott-Aldrich syndrome (WAS) is another X-linked immunodeficiency that affects cellular immunity [15]. Mutations in the WAS gene lead to defects in actin cytoskeleton remodeling, which is crucial for immune synapse formation in T cells. As a result, affected individuals experience recurrent infections, eczema, thrombocytopenia, and a heightened risk of autoimmune disease and malignancy [16]. T-cell dysfunction in WAS leads to impaired cytotoxic responses, making individuals more susceptible to viral infections and lymphoma development [17] Diamond-Blackfan anemia (DBA) is primarily known as a bone marrow failure syndrome affecting red blood cell production, but it also has significant immune implications [18] DBA is associated with impaired ribosomal function, which can lead to reduced numbers of circulating lymphocytes and altered immune responses. Patients with DBA have an increased risk of autoimmune disorders, reflecting the complex interplay between hematopoietic abnormalities and immune dysfunction [19] In hemoglobinopathies such as sickle cell disease (SCD) and thalassemia, chronic inflammation plays a central role in immune dysregulation [13] In SCD, recurrent vaso-occlusive crises and hemolysis lead to persistent inflammatory activation, which exhausts immune cells and impairs their function [20]. T cells from individuals with SCD often exhibit signs of chronic activation and exhaustion, reducing their ability to mount effective immune responses. Additionally, functional asplenia in SCD results in defective clearance of encapsulated bacteria, increasing susceptibility to infections such as pneumococcal and meningococcal disease [21].

Similarly, in thalassemia, chronic transfusion therapy leads to iron overload, which has detrimental effects on immune function. Excess iron promotes oxidative stress, damages immune cells, and alters cytokine signaling, further compromising cellular immunity. T-cell dysfunction, combined with iron-mediated oxidative stress, places individuals with thalassemia at increased risk for infections and immune dysregulation [22] Overall, cellular immunity is profoundly affected in congenital blood disorders, contributing to recurrent infections, chronic inflammation, and immune exhaustion [23]. A deeper understanding of these immune impairments is crucial for designing effective therapeutic strategies, such as immune modulation, vaccination protocols, and gene therapy approaches, to improve patient outcomes.

Humoral Immunity in Congenital Blood Disorders

Humoral immunity, which involves B cells and antibody production, is essential for long-term protection against infections [24]. In congenital blood disorders, B-cell dysfunction often results in impaired immunoglobulin production, leading to increased susceptibility to bacterial and viral infections [25]. The degree of immune impairment varies depending on the specific disorder, with some conditions causing significant antibody deficiencies and others affecting immune function indirectly through chronic inflammation and organ damage. Common variable immunodeficiency (CVID) is a congenital disorder characterized by defective B-cell differentiation and impaired immunoglobulin production [26]. This leads to recurrent bacterial infections, particularly of the respiratory and gastrointestinal tracts, as well as an increased risk of autoimmune diseases and lymphoproliferative disorders [22]. Patients with CVID often require immunoglobulin replacement therapy to restore protective antibody levels.

X-linked agammaglobulinemia (XLA) results from mutations in the Bruton's tyrosine kinase (BTK) gene, which is critical for B-cell development [27]. Individuals with XLA have significantly reduced or absent B cells, leading to very low immunoglobulin levels and a high susceptibility to bacterial infections. Without adequate antibody responses, these patients are prone to recurrent pneumonia, sinusitis, and chronic infections. Early diagnosis and immunoglobulin replacement therapy are crucial for managing this condition [28] In hemoglobinopathies such as sickle cell disease (SCD) and thalassemia, humoral immunity is compromised due to functional asplenia [29]. The spleen plays a vital role in filtering pathogens and mounting antibody responses against encapsulated bacteria such as Streptococcus pneumoniae and Haemophilus influenzae. Asplenia in these patients reduces their ability to clear infections, necessitating prophylactic antibiotics and vaccination to prevent life-threatening illnesses [30] Overall, humoral immune impairments in congenital blood disorders contribute to significant infection risks, underscoring the importance of early diagnosis, immunization, and targeted immunotherapy in affected individuals [31].

Impact of Bleeding Disorders on Immunity

Congenital bleeding disorders, including hemophilia A and B, von Willebrand disease (VWD), and Glanzmann thrombasthenia, primarily affect coagulation but also influence immune function [32] The interaction between hemostasis and immunity is complex, with various immunological consequences arising from disease pathophysiology and therapeutic interventions. One of the most significant immune challenges in hemophilia is the development of inhibitors against clotting factor replacement therapies [33]. These inhibitors are neutralizing antibodies that target exogenous factor VIII or IX, rendering treatment ineffective and complicating disease management. The risk of inhibitor development is influenced by genetic factors, treatment regimens, and immune system activation. Immune tolerance induction (ITI) therapy is often required to retrain the immune system and prevent persistent inhibitor formation [34]. Patients with bleeding disorders often require repeated blood transfusions, particularly in severe cases or in conditions like hemophilia with chronic joint bleeding and thalassemia with ineffective erythropoiesis [26]. Frequent transfusions increase the risk of alloimmunization, in which the immune system recognizes donor red blood cell or platelet antigens as foreign, leading to antibody formation. Alloimmunization can complicate future transfusions, necessitating careful donor matching and immunosuppressive strategies [28] Additionally, individuals with bleeding disorders are at higher risk of immune-mediated complications, including chronic inflammation and autoimmunity. The repeated use of clotting factor concentrates and blood products may trigger immune dysregulation, contributing to inflammatory conditions and increased susceptibility to infections [35] Understanding the immune consequences of congenital bleeding disorders is crucial for optimizing treatment strategies, preventing inhibitor formation, and managing transfusion-related complications to improve patient outcomes.

Therapeutic Strategies and Immune Modulation

Therapeutic strategies for congenital immune and hematologic disorders have increasingly focused on immune modulation to reduce complications and improve patient outcomes. Gene therapy has emerged as a promising approach to correct genetic defects in disorders such as severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS), and hemophilia [36] By targeting the underlying mutations, gene therapy offers a potential cure, though challenges such as vector safety and immune responses to modified cells remain. Bone marrow transplantation (BMT) remains the only curative option for many congenital immune and hematologic disorders. However, it carries significant risks, including graft-versus-host disease (GVHD) and opportunistic infections, necessitating careful patient selection and post-transplant management [37]. Immunoglobulin replacement therapy plays a crucial role in enhancing humoral immunity for patients with antibody deficiencies. Regular administration helps reduce infection risk and improves quality of life, particularly for those with primary immunodeficiencies [38] Vaccination strategies are essential in protecting immunocompromised individuals, particularly those with functional asplenia or antibody deficiencies. Tailored vaccine schedules, including non-live vaccines and passive immunization options, are critical in ensuring adequate protection while minimizing risks associated with live attenuated vaccines [39] Ongoing research continues to refine these therapeutic strategies, aiming to balance efficacy, safety, and long-term immune modulation.

CONCLUSION

Congenital blood and bleeding disorders disrupt both cellular and humoral immunity, increasing susceptibility to infections, autoimmunity, and immune dysregulation. A deeper understanding of

these immune impairments is essential for improving patient care and developing targeted therapies. Future research should prioritize advancements in gene therapy, refined immunomodulatory treatments, and optimized vaccination strategies. These efforts will help enhance immune function, reduce complications, and improve long-term outcomes for affected individuals. By integrating innovative approaches, the management of congenital immune disorders can become more effective, ultimately leading to better quality of life and survival rates.

REFERENCES

1. Van Stavern, G.P., Smith, L.D., James, H.R. (2021). Hematologic Disorders. In: Albert, D., Miller, J., Azar, D., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. 2021. https://doi.org/10.1007/978-3-319-90495-5_308-1
2. Alotiby A. Immunology of Stress: A Review Article. J Clin Med. 2024; 13(21):6394. doi: 10.3390/jcm13216394. PMID: 39518533; PMCID: PMC11546738.
3. Min'an Zhao, Jiayi Chu, Shiyao Feng, Chuanhao Guo, Baigong Xue, Kan He, Lisha Li, Immunological mechanisms of inflammatory diseases caused by gut microbiota dysbiosis: A review, Biomedicine & Pharmacotherapy, 2023; 164. 114985. https://doi.org/10.1016/j.biopha.2023.114985.
4. Hardtke-Wolenski, M., Landwehr-Kenzel, S. Tipping the balance in autoimmunity: are regulatory t cells the cause, the cure, or both?. *Mol Cell Pediatr*., 2024; **11**, 3. https://doi.org/10.1186/s40348-024-00176-8
5. Khambata K, Modi DN, Gupta SK. Immunoregulation in the testis and its implication in fertility and infections. Explor Immunol. 2021; 1:309-24. https://doi.org/10.37349/ei.2021.00021
6. Batabyal, R., Freishtat, N., Hill, E. *et al.* Metabolic dysfunction and immunometabolism in COVID-19 pathophysiology and therapeutics. *Int J Obes*., 2021; **45**, 1163–1169. https://doi.org/10.1038/s41366-021-00804-7
7. Ismail Sebina, Marion Pepper,Humoral immune responses to infection: common mechanisms and unique strategies to combat pathogen immune evasion tactics, Current Opinion in Immunology,2018; 51, 46-54. https://doi.org/10.1016/j.coi.2018.02.001.
8. Cox, R.J., Brokstad, K.A. Not just antibodies: B cells and T cells mediate immunity to COVID-19. *Nat Rev Immunol*., 2020; **20**, 581–582. https://doi.org/10.1038/s41577-020-00436-4
9. Pollard, A.J., Bijker, E.M. A guide to vaccinology: from basic principles to new developments. *Nat Rev Immunol*., 2021; **21**, 83–100. https://doi.org/10.1038/s41577-020-00479-7
10. Stewart P, Patel S, Comer A, Muneer S, Nawaz U, Quann V, Bansal M, Venketaraman V. Role of B Cells in Mycobacterium Tuberculosis Infection. *Vaccines*. 2023; 11(5):955. https://doi.org/10.3390/vaccines11050955
11. Marshall, J.S., Warrington, R., Watson, W. *et al.* An introduction to immunology and immunopathology. *Allergy Asthma Clin Immunol*., 2018; **14** (Suppl 2), 49. https://doi.org/10.1186/s13223-018-0278-1
12. Paludan, S.R., Pradeu, T., Masters, S.L. *et al.* Constitutive immune mechanisms: mediators of host defence and immune regulation. *Nat Rev Immunol*., 2021; **21**, 137–150. https://doi.org/10.1038/s41577-020-0391-5
13. Hernández-Chávez MJ, Pérez-García LA, Niño-Vega GA, Mora-Montes HM. Fungal Strategies to Evade the Host Immune Recognition. *Journal of Fungi*. 2017; 3(4):51. https://doi.org/10.3390/jof3040051
14. Kalman, L., Lindegren, M., Kobrynski, L. *et al.* Mutations in genes required for T-cell development:*IL7R*, *CD45*, *IL2RG*, *JAK3*, *RAG1*, *RAG2*, *ARTEMIS*, and *ADA* and severe combined immunodeficiency: HuGE review. *Genet Med*., 2004; 6, 16–26. https://doi.org/10.1097/01.GIM.0000105752.80592.A3
15. Ariga T. Wiskott-Aldrich syndrome; an x-linked primary immunodeficiency disease with unique and characteristic features. Allergol Int. 2012; 61(2):183-9. doi: 10.2332/allergolint.11-RAI-0412. Epub 2012 Feb 25. PMID: 22361515.
16. McCusker, C., Upton, J. & Warrington, R. Primary immunodeficiency. *Allergy Asthma Clin Immunol*., 2018; **14** (Suppl 2), 61. https://doi.org/10.1186/s13223-018-0290-5

17. Mongkonsritragoon W, Huang J, Fredrickson M, Seth D, Poowuttikul P. Positive Newborn Screening for Severe Combined Immunodeficiency: What Should the Pediatrician Do? Clinical Medicine Insights. 2023;17. doi:10.1177/11795565231162839
18. Liu, Y., Karlsson, S. Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia. *Leukemia*., 2024; **38**, 1–9. https://doi.org/10.1038/s41375-023-02082-w
19. Lipton JM, Ellis SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009; 23(2):261-82. doi: 10.1016/j.hoc.2009.01.004. PMID: 19327583; PMCID: PMC2886591.
20. Indolfi C, Dinardo G, Grella C, Klain A, Perrotta A, Mondillo G, Marrapodi MM, Decimo F, Miraglia Del Giudice M. Exploring the Interplay between Asthma and Hemoglobinopathies: A Comprehensive Review. J Clin Med. 2024; 13(11):3263. doi: 10.3390/jcm13113263. PMID: 38892971; PMCID: PMC11172992.
21. Ricerca BM, Di Girolamo A, Rund D. Infections in thalassemia and hemoglobinopathies: focus on therapy-related complications. Mediterr J Hematol Infect Dis. 2009; 1(1):e2009028. doi: 10.4084/MJHID.2009.028. PMID: 21415996; PMCID: PMC3033166.
22. Evangelidis P, Venou T-M, Fani B, Vlachaki E, Gavriilaki E on behalf of the International Hemoglobinopathy Research Network (INHERENT). Endocrinopathies in Hemoglobinopathies: What Is the Role of Iron? *International Journal of Molecular Sciences*. 2023; 24(22):16263. https://doi.org/10.3390/ijms242216263
23. Gbotosho OT, Gollamudi J, Hyacinth HI. The Role of Inflammation in The Cellular and Molecular Mechanisms of Cardiopulmonary Complications of Sickle Cell Disease. *Biomolecules*. 2023; 13(2):381. https://doi.org/10.3390/biom13020381
24. Sebina I, Pepper M. Humoral immune responses to infection: common mechanisms and unique strategies to combat pathogen immune evasion tactics. Curr Opin Immunol. 2018; 51:46-54. doi: 10.1016/j.coi.2018.02.001.
25. Akkaya, M., Kwak, K. & Pierce, S.K. B cell memory: building two walls of protection against pathogens. *Nat Rev Immunol*., 2020; **20**,229–238. https://doi.org/10.1038/s41577-019-0244-2
26. Familiar-Macedo D, de Azeredo EL, de Lemos ERS, Damasco PV, de-Oliveira-Pinto LM. Profile of Humoral Immunity and B Cell Pool in Infection with the SARS-CoV-2 Prototype Strain and AZD1222 (ChAdOx nCoV-19) Vaccination. *Vaccines*. 2025; 13(2):101. https://doi.org/10.3390/vaccines13020101
27. John W. Harvey, Chapter 6 - Immunohematology, Editor(s): John W. Harvey, Veterinary Hematology, W.B. Saunders, 2012; Pp 177-190. https://doi.org/10.1016/B978-1-4377-0173-9.00006-3.
28. Ponader S, Burger JA. Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. J Clin Oncol. 2014; 32(17):1830-9.doi: 10.1200/JCO.2013.53.1046. Epub 2014 Apr 28. PMID: 24778403; PMCID: PMC5073382.
29. Zheng B, Zhang Y, Jin Y, Yu H. A novel Bruton's tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia. BMC Pediatr. 2014; 14:265. doi: 10.1186/1471-2431-14-265. PMID: 25316352; PMCID: PMC4286934.
30. Chawla, S., Jindal, A.K., Arora, K. *et al.* T Cell Abnormalities in X-Linked Agammaglobulinaemia: An Updated Review. *Clinic Rev Allerg Immunol*., 2023; **65**, 31–42. https://doi.org/10.1007/s12016-022-08949-7
31. Dodds WJ. One Health: Animal Models of Heritable Human Bleeding Diseases. *Animals*. 2023; 13(1):87. https://doi.org/10.3390/ani13010087
32. McCulloch R, Smith MP. Bleeding disorders. InnovAiT. 2014; 7(9):549-557. doi:10.1177/1755738014532804
33. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013; 4(1):59-72. doi: 10.1177/2040620712464509. PMID: 23610614; PMCID: PMC3629762.
34. Meeks SL, Batsuli G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016; (1):657-662. doi:

10.1182/asheducation-2016.1.657. PMID: 27913543; PMCID: PMC6142469.

35. Margareth C. Ozelo, Gabriela G. Yamaguti-Hayakawa, Impact of novel hemophilia therapies around the world, Research and Practice in Thrombosis and Haemostasis, 2022; 6(3): e12695. https://doi.org/10.1002/rth2.12695.
36. Fischer A, Hacein-Bey-Abina S. Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med. 2020; 217(2):e20190607. doi: 10.1084/jem.20190607. PMID: 31826240; PMCID: PMC7041706.
37. Kohn DB, Chen YY, Spencer MJ. Successes and challenges in clinical gene therapy. Gene Ther. 2023; 30(10-11):738-746. doi: 10.1038/s41434-023-00390-5. Epub 2023 Nov 8. PMID: 37935854; PMCID: PMC10678346.
38. Deng, HX., Wang, Y., Ding, Qr. *et al.* Gene therapy research in Asia. *Gene Ther.*, 2017; **24**, 572–577. https://doi.org/10.1038/gt.2017.62
39. Ay, C., Reinisch, A. Gene therapy: principles, challenges and use in clinical practice. *Wien Klin Wochenschr* (2024). https://doi.org/10.1007/s00508-024-02368-8

CITE AS: Nagawa Jackline Irene (2025). Cellular and Humoral Immunity in Congenital Blood and Bleeding Disorders. IDOSR JOURNAL OF BIOLOGY, CHEMISTRY AND PHARMACY 10(1):30-35. https://doi.org/10.59298/IDOSR/JBCP/25/101.303500